Due to mutation, nuclear and cytoplasmatic levels of p53 are strongly increased in tumor cells compared to normal cells, thereby providing an immunological window for p53 wild-type specific immune effector cells [76,77]. This evidence concerns the gene TP53 and neoplasm.